替拉替尼相关中毒性表皮坏死松解一例报告及文献复习。

Q3 Medicine
Skin health and disease Pub Date : 2025-04-04 eCollection Date: 2025-04-01 DOI:10.1093/skinhd/vzaf011
Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada
{"title":"替拉替尼相关中毒性表皮坏死松解一例报告及文献复习。","authors":"Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada","doi":"10.1093/skinhd/vzaf011","DOIUrl":null,"url":null,"abstract":"<p><p>Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8<sup>+</sup> T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 2","pages":"151-153"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068473/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature.\",\"authors\":\"Noriko Ikegawa, Natsuko Saito-Sasaki, Yu Sawada\",\"doi\":\"10.1093/skinhd/vzaf011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8<sup>+</sup> T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.</p>\",\"PeriodicalId\":74804,\"journal\":{\"name\":\"Skin health and disease\",\"volume\":\"5 2\",\"pages\":\"151-153\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068473/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin health and disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/skinhd/vzaf011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/skinhd/vzaf011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

替拉替尼是一种布鲁顿酪氨酸激酶(BTK)抑制剂,对复发性或难治性弥漫性大b细胞淋巴瘤(DLBCL)有疗效。然而,严重的药疹,包括中毒性表皮坏死松解(TEN)也有报道。我们提出一个74岁的难治性DLBCL患者,在接受替拉替尼治疗1个月后发展为TEN。与替拉鲁替尼有关的严重药疹很少见,只有三例报告,包括我们的病例。Tirabrutinib选择性抑制BTK可能激活细胞毒性CD8+ T细胞,促进Stevens-Johnson综合征/TEN发病机制。需要进一步的研究来阐明BTK抑制剂相关药疹的机制并开发更好的诊断方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tirabrutinib-associated toxic epidermal necrolysis: a case report and review of the literature.

Tirabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in recurrent or refractory diffuse large B-cell lymphoma (DLBCL). However, severe drug eruptions, including toxic epidermal necrolysis (TEN), have been reported. We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment. Severe drug eruptions linked to tirabrutinib are rare, with only three cases reported, including ours. Tirabrutinib's selective BTK inhibition may activate cytotoxic CD8+ T cells, contributing to Stevens-Johnson syndrome/TEN pathogenesis. Further studies are needed to clarify the mechanisms and develop better diagnostic approaches for BTK inhibitor-related drug eruptions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信